Back to targets

Target detail

REST

RE1 silencing transcription factor

Data: Live structured evidence (Supabase)

Marker index metadata

Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).

Display name: RE1 silencing transcription factor

Aliases: REST, RE1 silencing transcription factor

Type / organism: protein_coding · Homo sapiens

Source: opentargets · ENSG00000084093

Index freshness: last_synced_at 2026-05-15T19:14:12.217+00:00 · updated 2026-05-15T19:14:12.745753+00:00

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Target index (foundation)

This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.

Live structured evidence · sources

Connectors represented in loaded rows for REST. Empty groups mean no matching rows — not a claim about biology or clinical use.

  • ClinicalTrials.govLive when indexed

    Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.

  • Open TargetsLive when indexed

    Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).

Open Targets · disease–target evidence

Rows from disease_target_evidence for this symbol.

glioblastoma

literature · opentargets

ChEMBL · linked drugs (drug_targets)

Drug records tied via drug_targets — mechanistic linkage only.

No linked drug rows

When drug_targets and drugs rows exist for this symbol, they are listed here.

repoDB-style · approved-elsewhere discussion candidates

disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.

No matching rows

Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.

ClinicalTrials.gov · trial-matched options

Mirror rows whose text fields mention this symbol — registry context only.

NCT01700569 — Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma

Status: TERMINATED · clinicaltrials.gov

Open trials hub

NCT04209790 — Neoadjuvant Chemoradiation for Resectable Glioblastoma

Status: TERMINATED · clinicaltrials.gov

Open trials hub

NCT06059690 — Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Status: RECRUITING · clinicaltrials.gov

Open trials hub

NCT01865162 — Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

Status: COMPLETED · clinicaltrials.gov

Open trials hub

NCT01062399 — Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Status: COMPLETED · clinicaltrials.gov

Open trials hub

NCT04846257 — Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence

Status: COMPLETED · clinicaltrials.gov

Open trials hub

NCT03466450 — Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma

Status: COMPLETED · clinicaltrials.gov

Open trials hub

NCT06359379 — Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Status: TERMINATED · clinicaltrials.gov

Open trials hub

NCT06264388 — DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Status: RECRUITING · clinicaltrials.gov

Open trials hub
CANTI signal builder · target-linked research signals

Repurposing signal rows for drugs linked to this target via drug_targets.

No research signals for linked drugs

Run the deterministic signal builder after drug_targets and source rows are present.

Caution / negative-evidence rows

Structured rows with negative evidence_direction on disease–drug or signal tables.

No negative-direction rows

When structured evidence includes explicit negative direction fields, they surface here for oncology review.

Missing evidence · row counts by source string
  • clinicaltrials.gov: 9
  • opentargets: 1
Summary row (aggregated list)

Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.

Disease contexts

0

Linked drugs

0

Linked in dataset

0

Research signals

0

Evidence badges (illustrative)

Doctor-discussion candidate and related tags are descriptive only.

Appears in source landscapeLinked in datasetRequires oncology review
Linked research signals (list read)

Signals list: Live structured evidence (Supabase)

No matching live evidence found

When repurposing_signal rows reference this marker via linked drugs, summaries appear here.